HONG KONG, Dec. 11, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in ...
HONG KONG, Sept. 22, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) is excited to announce that the Late-Breaking Abstract (LBA) from the registrational Phase III clinical study (AK112-306/HARMONi-6 study) ...
Akeso’s cadonilimab has outperformed the activity of the current standard of care (SoC) treatment option during a real-world study in first-line gastric or gastroesophageal cancer. The AK104-302 trial ...
Continuation of serplulimab-based therapy beyond first progression in advanced gastric/gastroesophageal junction (G/GEJ) cancer: Preliminary results from the SCAFIGC trial. This is an ASCO Meeting ...
- China has the highest number of cases and deaths from gastric cancer of any country worldwide 1 - - Zolbetuximab is the first and only therapy approved in China to target claudin 18.2, a biomarker ...
MedPage Today on MSN
Novel treatments for gastric cancer
Immunotherapy, targeted treatments, HIPEC, and new delivery options ...
MedPage Today on MSN
For Your Patients: A Look at Promising New Treatments for Gastric Cancer
Emerging immunotherapies and targeted therapies take aim at recently identified biomarkers ...
New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence ...
These low and negative PD-L1 patients constitute well more than half of the total gastric cancer patient population. In 2024, the FDA narrowed the indication for all approved PD-1 inhibitors in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results